PharmaLogic Holdings Corp.

PharmaLogic Holdings Corp., established in 1993, is a prominent player in the pharmaceutical industry, focusing on the development and manufacture of diagnostic imaging agents and radiotherapeutics for cancer treatments. The company's mission revolves around providing reliable and high-quality solutions to improve patient management in the medical field. With a network of over 40 radiopharmacies and 9 cyclotrons spread across the United States and Canada, PharmaLogic stands out as the second-largest CDMO in North America. This extensive infrastructure underscores the company's commitment to ensuring accessibility and efficiency in the delivery of its products and services. Moreover, PharmaLogic's expertise spans the entire drug development lifecycle, from discovery to manufacturing and commercialization, enabling them to offer a comprehensive and seamless approach to their offerings. This expertise is further complemented by their established and reliable network of radiopharmacies, providing a solid foundation for their operations. The company's dedication to advancing radiopharmaceutical technology positions PharmaLogic as a key player in driving innovation in this critical field, with the overarching aim of benefiting patients globally. In conclusion, PharmaLogic Holdings Corp.'s robust infrastructure, industry expertise, and commitment to innovation make it a compelling entity in the pharmaceutical landscape, with immense potential for growth and impact. For more information, visit: www.radiopharmacy.com.